Chronic intestinal pseudo-obstruction

Digestive Diseases

Volumn 18, Issue 2, 2000, Pages 83-92

  Hirano, Ikuo ^a   Pandolfino, John ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Colonic dysmotility; Constipation; Hirschsprung's disease; Ileus; Megacolon; Mitochondrial neurogastrointestinal encephalomyopathy; Motility; Motility disorders; Ogilvie's syndrome; Pseudo obstruction

Indexed keywords

ALOSETRON; CEPHALOSPORIN DERIVATIVE; CISAPRIDE; ERYTHROMYCIN; METRONIDAZOLE; MISOPROSTOL; MOTILIN; PROSTAGLANDIN E1 DERIVATIVE; PRUCALAPRIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; TEGASEROD; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; CHAGAS DISEASE; DISEASE CLASSIFICATION; HIRSCHSPRUNG DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINE OBSTRUCTION; INTESTINE PSEUDOOBSTRUCTION; NEUROTRANSMITTER RELEASE; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SYNDROME DELINEATION;

EID: 0033768217     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000016969     Document Type: Review

References (45)

1. Disorders of gastrointestinal motility in neurologic diseases
2. Pathology of neuromuscular disorders of the small intestine and colon
3. The genetics of Hirschsprung's disease. Evidence for heterogeneous etiology and a study of sixty-three families
4. Studies of distal colonic motility in children. III. The pathologic physiology of congenital megacolon
5. Nitric oxide synthase distribution in the enteric nervous system of Hirschsprung's disease
6. Mutations of the RET proto-oncogene in Hirschsprung's disease
7. Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease
8. Various mechanisms cause RET-mediated signaling defects in Hirschsprung's disease
9. Loss of function effect of RET mutations causing Hirschsprung disease
10. Nonsurgical test for the diagnosis of Hirschsprung's disease
11. Manometry and histochemistry in the diagnosis of Hirschsprung's disease
12. Mechanisms of disease: The enteric nervous system
13. Alimentary tract manifestations of multiple endocrine neoplasia, type 2b
14. Alimentary-tract ganglioneuromatosis. A major component of the syndrome of multiple endocrine neoplasia, type 2b
15. Multiple endocrine neoplasia (MEN) syndrome type IIB: Gastrointestinal manifestations
16. Seminars in medicine of the Beth Israel Hospital, Boston. RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease
17. Multiple system atrophy with neuronal intranuclear hyaline inclusions. Report of a case and review of the literature
18. A familial visceral myopathy with dilatation of the entire gastrointestinal tract
19. Studies of idiopathic intestinal pseudoobstruction. II. Hereditary hollow visceral myopathy: Family studies
20. Progressive systemic sclerosis of the gastrointestinal tract and hereditary hollow visceral myopathy: Two distinguishable disorders of intestinal smooth muscle
21. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): Clinical, biochemical, and genetic features of an autosomal recessive mitochondrial disorder
22. Mitochondrial neurogastrointestinal encephalomyopathy: Manometric and diagnostic features
23. Mitochondrial neurogastrointestinal encephalomyopathy: Diagnosis by rectal biopsy
24. Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder
25. Functional implications of circulating muscarinic cholinergic receptor autoantibodies in chagasic patients with achalasia
26. Gastrointestinal manifestations of Chagas' disease
27. Paralysis of digestive tract with lesions of myenteric plexuses. A new paraneoplastic syndrome
28. Enteric neuronal autoantibodies in pseudoobstruction with small-cell lung carcinoma
29. Acquired intestinal aganglionosis and circulating autoantibodies without neoplasia or other neural involvement
30. Oesophageal manometry in the evaluation of megacolon with onset in adult life
31. Impaired transit of chyme in chronic intestinal pseudoobstruction. Correction by cisapride
32. Functional gut disorders: From motility to sensitivity disorders. A review of current and investigational drugs for their management
33. A comparison of two cohort studies evaluating the safety of cisapride: Prescription-event monitoring and a large phase IV study
34. The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada
35. Effect of different prokinetic agents and a novel enterokinetic agent on postoperative ileus in rats
36. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans
37. Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction
38. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma
39. Clinical pharmacology forum: Motility agents and the gastrointestinal tract
40. Misoprostol in the treatment of chronic refractory constipation: Results of a long-term open label trial
41. Neostigmine for the treatment of acute colonic pseudo-obstruction
42. Surgical treatment in familial visceral myopathy
43. Chronic idiopathic intestinal pseudo-obstruction. A surgical approach
44. Surgery for idiopathic megarectum and megacolon
45. Evaluation and surgical treatment of severe chronic constipation